Randomised controlled trial
Empagliflozin after Acute Myocardial Infarction
- Randomised controlled trial
- event-driven
- double-blind
- placebo-controlled
Authors' conclusion
Among patients at increased risk for heart failure after acute myocardial infarction, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for heart failure or death from any cause than placebo.
Study context
- Population
- Patients hospitalized for acute MI at risk for HF
- Participants
- 3,260 vs 3,262
- Comparison
- Empagliflozin vs placebo
- Empagliflozinn = 3,260
- Placebon = 3,262reference
- Primary endpoint
- Composite of:
- Hospitalization for HF
- Death from any cause (time-to-first-event)
- Follow-up
- Median 17.9 months
Primary result
As reported in the abstract
Hazard ratio
0.90
95% CI 0.76–1.06
P = 0.21
Events by treatment group
Empagliflozin vs Placebo
HR 0.90 (95% CI 0.76–1.06); P = 0.21
Further findings
| Outcome | Empagliflozin | Placebo | HR (95% CI) | |
|---|---|---|---|---|
| First hospitalization for HF (primary component) | 3.6% | 4.7% | 0.77 (0.60–0.98) | |
| Death from any cause (primary component) | 5.2% | 5.5% | 0.96 (0.78–1.19) | |
| 0.512Hazard ratio (log scale) |
Safety
Adverse events
- Consistent with the known safety profile of empagliflozin and similar in the two groups
Original publication
Empagliflozin after Acute Myocardial Infarction. N Engl J Med. Published 6 April 2024. doi:10.1056/nejmoa2314051
Summarised from the published abstract; every number is checked against it